Ventria Bioscience supports the Biotechnology Industry Organization (BIO) in developing standards for plant-made pharmaceuticals
SACRAMENTO, Calif. Ventria Bioscience supports the effort of BIO to develop industry-wide standards for the production of plant-made pharmaceuticals and industrials. BIO's recent position statement affects the use of "outcrossing" plants for the production of plant-made pharmaceuticals and industrials.
Outcrossing plants reproduce by wind or insect pollination. In contrast, plant-made pharmaceuticals and industrials can also be produced using self-pollinating plants such as soybeans, rice and barley. These self-pollinating plants do not require the wind or insects for pollination.
"The use of plant systems to produce biopharmaceutical proteins and peptides is an important technology in the fight against human disease and it is quite appropriate that BIO take a leadership role in defining the standards for plant-made pharmaceutical production," said William J. Rutter, Ph.D., Ventria Board Member.
"Ventria's ExpressTec(TM) system is an ideal solution for the production of plant-made pharmaceuticals and industrials because it utilizes self-pollinating plants to produce biopharmaceuticals," said Scott Deeter, President & CEO, Ventria Bioscience.
Other news from the department research and development
